Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

pharmaphorum

JANUARY 16, 2023

Hormone replacement therapy (HRT) could cut the risk of Alzheimer’s in some women at elevated risk of the disease, according to researchers in the UK. Their work specifically focused on the effect of HRT on women with the APOE4 genotype.

Hormones 75

Hormones Genotype Research Genetics 75

XTalks

MARCH 29, 2021

The results did not differ based on fast or slow caffeine metabolism genotype. They also believe caffeine could potentially disrupt fetal stress hormones, putting infants at risk for rapid weight gain after birth and for chronic conditions such as obesity, heart disease and diabetes later on in life.

Genotype 98

Genotype Allergies Hormones Research 98

XTalks

SEPTEMBER 15, 2020

In addition to the vaccine, the company is also developing an investigational drug called Remygen for the regeneration of endogenous insulin production and to improve hormonal response to hypoglycemia; trials to test the treatment are currently ongoing in patients that have been living with type 1 diabetes for more than five years.

Vaccination 87

Vaccination Vaccine Insulin Trials 87

The Pharma Data

APRIL 14, 2021

Trodelvy is also being developed as an investigational treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer. Beyond the regulatory approvals of Trodelvy in the U.S.,

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52

The Pharma Data

APRIL 7, 2021

Trodelvy is also being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway.

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

DECEMBER 9, 2020

The aim of the research will be to create a TGS IVD platform by optimizing a multi-layer approach encompassing the initial sample and library preparation, state-of-the-art sequencing technologies and improved genotyping procedures. osteolabs – Germany’s osteolabs GmbH raised €1.6 million in a second financing round.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52